LON:VAL - ValiRx Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ValiRx Plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 0.11 +0.01 (+10.00 %) (As of 01/21/2020 02:51 AM ET) Add Compare Today's Range 0.10Now: GBX 0.11▼ 0.1250-Day Range 0.10MA: GBX 0.12▼ 0.1452-Week Range 0.09Now: GBX 0.11▼ 1.33Volume52.31 million shsAverage Volume3.82 million shsMarket Capitalization£1.47 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartEarningsHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Read More… Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:VAL Previous Symbol CUSIPN/A CIKN/A Webhttp://www.valirx.com/ Phone+44-20-30084416Debt Debt-to-Equity Ratio6.37 Current Ratio0.95 Quick Ratio0.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.07 per share Price / Cash Flow1.49 Book ValueGBX 0.30 per share Price / Book0.37Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees12 Outstanding Shares1,334,829,952Market Cap£1.47 million Next Earnings DateN/A OptionableNot Optionable Receive VAL News and Ratings via Email Sign-up to receive the latest news and ratings for VAL and its competitors with MarketBeat's FREE daily newsletter. LSE:VAL Rates by TradingView ValiRx (LON:VAL) Frequently Asked Questions What is ValiRx's stock symbol? ValiRx trades on the London Stock Exchange (LON) under the ticker symbol "VAL." How were ValiRx's earnings last quarter? ValiRx Plc (LON:VAL) announced its quarterly earnings data on Tuesday, April, 10th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.60) by $0.70. View ValiRx's Earnings History. Has ValiRx been receiving favorable news coverage? Media coverage about VAL stock has been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ValiRx earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for ValiRx. Who are some of ValiRx's key competitors? Some companies that are related to ValiRx include Innovotech (IOT), Fiji Kava (FIJ), Hemostemix (HEM), Amplia Therapeutics (ATX), Factor Therapeutics (FTT), Pascal Biosciences (PAS), Netscientific (NSCI), CAN-FITE BIOPHA/S (CANF), Can-Fite Biopharma (CANF), Revive Therapeutics (RVV), IBEX Technologies (IBT), BPH Energy (BPH), Physiomics (PYC), Hemispherx BioPharma (HEB) and ImmunoCellular Therapeutics (IMUC). What other stocks do shareholders of ValiRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other ValiRx investors own include Petrofac (PFC), Boohoo Group (BOO), ReNeuron Group (RENE), Falanx Group (FLX), Solo Oil (SOLO), Cyanconnode (CYAN), IQE (IQE), Lloyds Banking Group (LLOY), Eckoh (ECK) and Sareum (SAR). Who are ValiRx's key executives? ValiRx's management team includes the folowing people: Dr. Satu Vainikka, Founding Director & CEO (Age 52)Mr. James Gerry Desler, Founding Director & CFO (Age 63)Dr. George Morris, Founding Director & COO (Age 63)Mr. Kevin Alexander, Sec. & Non-Exec. Director (Age 63)Mr. Tarquin Edwards, Head of Investor Relations & Communications How do I buy shares of ValiRx? Shares of VAL and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is ValiRx's stock price today? One share of VAL stock can currently be purchased for approximately GBX 0.11. How big of a company is ValiRx? ValiRx has a market capitalization of £1.47 million. ValiRx employs 12 workers across the globe.View Additional Information About ValiRx. What is ValiRx's official website? The official website for ValiRx is http://www.valirx.com/. How can I contact ValiRx? ValiRx's mailing address is 3rd Fl, 16 Upper Woburn Place, LONDON, WC1H 0BS, United Kingdom. The company can be reached via phone at +44-20-30084416. MarketBeat Community Rating for ValiRx (LON VAL)Community Ranking: 1.7 out of 5 ()Outperform Votes: 144 (Vote Outperform)Underperform Votes: 268 (Vote Underperform)Total Votes: 412MarketBeat's community ratings are surveys of what our community members think about ValiRx and other stocks. Vote "Outperform" if you believe VAL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VAL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/21/2020 by MarketBeat.com StaffFeatured Article: How do candlesticks reflect price movement?
